Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Alison_Finger
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
immunotherapy
gene therapy natural killer (NK) cell therapies |
| gptkbp:foundedIn |
2019
|
| gptkbp:fundedBy |
$42 million Series A
|
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Catamaran Bio
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:Lightstone_Ventures
gptkb:M_Ventures gptkb:Astellas_Venture_Management gptkb:Mass_General_Brigham_Ventures gptkb:SV_Health_Investors gptkb:Sofinnova_Partners gptkb:Takeda_Ventures |
| gptkbp:products |
engineered NK cell therapies for cancer
|
| gptkbp:website |
https://www.catamaranbio.com/
|
| gptkbp:bfsParent |
gptkb:Mark_Leschly
|
| gptkbp:bfsLayer |
6
|